Home › Research › Costs and economics
Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration
Ozawa T, Franguridi G, Mattke S. Journal of Prevention of Alzheimer's Disease, 2024
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Multiple disease modifying treatment for Alzheimer's disease are currently in clinical development or have been recently approved for use. They have vastly different treatment properties but so far, little work has been done to quantify the impact of treatment properties on the treatment's value in terms of medical and social care costs and caregiver burden. Objectives This study aims to analyze how the mode of treatment administration, treatment frequency and duration, and monitoring requirements affect the value of disease modifying treatments. In order to isolate these effects, we compare five hypothetical disease modifying treatments with equal efficacy and safety: (1) chronic bi-weekly intravenous infusion, (2) chronic four-weekly intravenous infusion, (3) 52 weeks fixed duration four-weekly intravenous infusion, (4) chronic subcutaneous injections, and (5) chronic oral prescription on their direct medical costs, caregiver burden, and preservation of treatment value. Design Survey of Alzheimer's disease treatment clinics and retrospective data analysis. Setting United States. Measurements Direct medical cost and caregiver burden of treatment administration and monitoring compared to gross treatment benefit. Results Chronic bi-weekly infusion treatment had the highest direct medical cost ($45,208) and caregiver burden ($6,095), reducing the treatment value by 44%, while oral treatment with the lowest direct medical cost ($1,983) and caregiver burden ($457) reduced the treatment value by only 2%. Substantial caregiver burden was reported from the survey, with a reported average of 2.3 hours for an office visit and infusion, 44 minutes of round-trip travel time, and 78% of patients being accompanied by a caregiver for treatment. Conclusion Burden of chronic intravenous treatments exceed the gross medical and social care cost savings and value of caregiver benefit. The results suggest the need for less complex treatments that require fewer clinic visits to preserve the economic value of disease modifying treatments.
What this study adds
Evidence grade: Preliminary
Comparing five hypothetical disease-modifying treatments with equal efficacy and safety, chronic bi-weekly intravenous infusion had the highest direct medical cost and caregiver burden and reduced treatment value by 44%, while oral treatment reduced treatment value by only 2%. Reported effect size: Treatment value reduced by 44% (bi-weekly infusion) vs 2% (oral).
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ozawa, T., Franguridi, G., & Mattke, S. (2024). Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration. Journal of Prevention of Alzheimer's Disease. https://doi.org/10.14283/jpad.2024.81
Vancouver
Ozawa T, Franguridi G, Mattke S. Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration. Journal of Prevention of Alzheimer's Disease. 2024. doi:10.14283/jpad.2024.81. PMID: 39350384.
BibTeX
@article{ozawa2024-39350384,
author = {Ozawa, T. and Franguridi, G. and Mattke, S.},
title = {{Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration}},
journal = {Journal of Prevention of Alzheimer's Disease},
year = {2024},
doi = {10.14283/jpad.2024.81},
pmid = {39350384},
url = {https://doi.org/10.14283/jpad.2024.81}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Measurements Direct medical cost and caregiver burden of treatment administration and monitoring compared to gross treatment benefit.
- Results Chronic bi-weekly infusion treatment had the highest direct medical cost ($45,208) and caregiver burden ($6,095), reducing the treatment value by 44%, while oral treatment with the lowest direct medical cost ($1,983) and caregiver burden ($457) reduced the treatment value by only 2%.
- The results suggest the need for less complex treatments that require fewer clinic visits to preserve the economic value of disease modifying treatments.
Why it matters
Comparing five hypothetical disease-modifying treatments with equal efficacy and safety, chronic bi-weekly intravenous infusion had the highest direct medical cost and caregiver burden and reduced treatment value by 44%, while oral treatment reduced treatment value by only 2%. Because the treatments compared were hypothetical and assumed equally effective, this work addresses how administration route and monitoring affect cost and caregiver burden, not whether any treatment works.
New to this subject? Start with our plain-English guide: Costs & economics →
Study details
- Study designmodelling
- Effect sizeTreatment value reduced by 44% (bi-weekly infusion) vs 2% (oral)
- Evidence strengthPreliminary
Limitations
A stylised comparison of hypothetical treatments rather than actual products, ignoring differences in effect size, adverse events and eligibility; discontinuation rates were disregarded; caregiver burden came from a survey of clinic staff rather than time-use data; and caregiver time for injections and prescription refills was not counted, possibly underestimating subcutaneous and oral burden.
How this study scored 44/100
Published in a peer-reviewed journal, and it is a computer model rather than new measurements. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 43 of the 98 points we could judge it on, which is 44 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Prevention of Alzheimer's Disease) |
| Journal's citation record | 0 / 4 | The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29) |
| Study design | 3 / 12 | A computer model rather than new measurements |
| Strength of evidence | 2 / 5 | Rated “preliminary” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 13 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.2 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 3 / 6 | Cited 3.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Soeren Mattke: h-index 50 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Southern California: institution h-index 1,521 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39350384) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 43 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 43 of the 98 points we could judge it on is 44 out of 100. |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Costs and economics from nearby years
Also in Costs and economics
21 studies in the library are filed under Costs and economics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Costs and economics hub.